Gilead Sciences, Inc. (GILD) a biopharmaceutical company, Thursday announced that it has returned to profitability in the first quarter of 2025, reporting net income of $1.32 billion or earnings per share of $1.04, compared to a net loss of $4.17 billion or loss per share of $3.34 in the same quarter last year.
The sharp turnaround was primarily driven by the absence of large in-process R&D charges that had weighed on results a year earlier.
Total revenue held steady at $6.67 billion versus $6.69 billion in the prior year period. Product sales were essentially flat at $6.61 billion, while royalty and other revenues grew modestly.
GILD closed Wednesday's trading at $106.15 down $0.23 or 0.22 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.